ASHINGTON — Patient groups and drug manufacturers say a proposed rule from the Center for Medicare and Medicaid Services would dramatically restrict coverage of genetic tests for patients covered by those programs — a move which may specifically impact patients deciding between various cancer treatments.

The rule, expected to be finalized next week, stipulates that CMS only cover next-generation sequencing (NGS) tests approved by the Food and Drug Administration. That would leave a small subset of existing diagnostic tools — including the FoundationOne, Oncomine Dx, and Illumina — available to Medicare beneficiaries.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Drug Pricing
Donald Trump

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.